Pregled bibliografske jedinice broj: 1242069
Thromboprophylaxis for COVID-19-related coagulopathy: what next?
Thromboprophylaxis for COVID-19-related coagulopathy: what next? // European Heart Journal-Cardiovascular Pharmacotherapy, 8 (2022), 3; 336-337 doi:10.1093/ehjcvp/pvac009 (međunarodna recenzija, pismo, stručni)
CROSBI ID: 1242069 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Thromboprophylaxis for COVID-19-related
coagulopathy: what next?
Autori
Čulić, Viktor ; Vio, Riccardo ; Proietti, Riccardo
Izvornik
European Heart Journal-Cardiovascular Pharmacotherapy (2055-6837) 8
(2022), 3;
336-337
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo, stručni
Ključne riječi
COVID-19 ; Thromboprophylaxis
Sažetak
Patients hospitalized with COVID-19 are at high risk for microand macrovascular thromboembolic events due to thromboinflammation and the coagulopathy caused by SARS-CoV-2. Current evidence suggests that anticoagulants other than heparin or antiplatelet therapy do not provide a beneficial effect, but combinations of anticoagulation regimens may be clinically tested. A better distinction between moderate and severe disease should be made, particularly with regard to lung injury and oxygen requirement.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
